Thursday, May 28, 2015 8:04:34 AM
Source: Business Wire
Clinical utility and clinical validation of CTCs and ctDNA to analyze cancer biomarkers ALK, ROS1 and EGFR demonstrated
Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, continues to build evidence of the clinical utility of its liquid biopsy offerings with an abstract at the 2015 Annual American Society of Clinical Oncology Meeting in Chicago starting on May 29, 2015.
Biocept offers a sensitive and quantitative blood-based method for the detection and monitoring of clinically actionable cancer biomarkers in order to help doctors make treatment decisions based on genomic information gained from the tumor material. The Company is engaged in multiple clinical studies designed to demonstrate the utility of its liquid biopsy diagnostic to detect a patient’s biomarker status and for the assessment of treatment response over time.
The abstract demonstrates the clinical utility of a liquid biopsy using Biocept’s technology, not only for a patient where there is insufficient tissue from a biopsy, but also in order to better represent a patient’s biomarker status by avoiding challenges associated with tissue heterogeneity, all accomplished with a simple blood draw.
"By providing oncologists such as myself with genomic testing results performed on a simple blood test, we are able to stratify patients based on biomarker status in real-time, which has the potential to drastically change how patients with solid cancers such as non-small cell lung cancers (NSCLC) are monitored," stated Dr. Lyudmila Bazhenova, MD, Associate Clinical Professor of Medicine at University of California, San Diego Moores Cancer Center.
"The ease of real-time monitoring and early identification of the emergence of resistance reduces the time to make a treatment change, which in a setting of metastatic cancer, is crucial. Additionally, the health economic benefit of obtaining actionable biomarker status from a simple blood draw in lieu of a surgical procedure is an added advantage to our health care system,” stated Veena Singh, MD, Sr. VP and Medical Director at Biocept.
The abstract also highlights the Biocept platform’s ability to provide subsequent serial monitoring of biomarker status after therapy to monitor clinical response as well as progression. “This is an important feature of the platform,” noted Dr. Singh. “Emerging therapies such as rociletinib and AZD9291 are in advanced clinical development and have been shown to benefit patients with T790M mutations, another biomarker associated with lung cancer. As the next-generation of therapies come to market, it will be important that clinicians have a method to perform serial monitoring on patients in order to understand when they are candidates for these therapies. At Biocept, we offer a test to detect these biomarkers.”
Recent BIOCQ News
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 11/20/2023 01:47:57 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM